Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 19/20 | 0.68 |
| ▸ | GRPR | P30550 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19492277 | 0.97 | IL23R (0.66) | IL23RGRPR | |
| SCHEMBL16263007 | 0.96 | IL23R (0.63) | IL23RGRPR | |
| SCHEMBL26713961 | 0.91 | IL23R (0.58) | IL23RGRPR | |
| SCHEMBL7156278 | 0.88 | IL23R (0.63) | IL23RGRPR | |
| SCHEMBL31433169 | 0.87 | IL23R (0.66) | IL23R | |
| SCHEMBL24945842 | 0.86 | IL23R (0.60) | IL23RGRPR | |
| SCHEMBL30883264 | 0.86 | IL23R (0.67) | IL23R | |
| SCHEMBL31275967 | 0.86 | RXFP1 (0.65) | IL23RGRPR | |
| SCHEMBL31433168 | 0.85 | IL23R (0.64) | IL23R | |
| SCHEMBL30026081 | 0.85 | ERAP2 (0.59) | IL23RGRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140363375-A1 | ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATION | PROMEGA CORPORATION (US) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140363375-A1 | ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATION | GLB1, MRPL21, LRBA | IL23R 3253/4885GRPR 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.